Alzheimer's drug trial cut short: SPG302 long-term study terminated
NCT ID NCT06833281
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 23 times
Summary
This study aimed to see if taking SPG302 daily for a long time is safe and helps slow Alzheimer's in people with mild-to-moderate symptoms. It included 12 adults who had already been in an earlier SPG302 study. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flinders Medical Center
Adelaide, South Australia, 5000, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
Conditions
Explore the condition pages connected to this study.